SIRPγ Inhibitor for Cancer Treatment | US12599650B2
Summary
USPTO granted patent US12599650B2 to AMGEN INC. covering methods of treating tumors or cancer using SIRPγ inhibitors. The patent, invented by Ruozhen Hu, Paolo Manzanillo, and Wenjun Ouyang, contains 9 claims. Filing date was June 23, 2020 (Application No. 17618922).
What changed
USPTO granted patent US12599650B2 to AMGEN INC. on April 14, 2026. The patent covers methods of treating tumors or cancer by administering a SIRPγ binder to increase immune response against the tumor or cancer, or to increase effector activity or reduce suppressive activity of T-cells in a subject.
Affected parties include pharmaceutical companies and drug manufacturers developing cancer immunotherapies. The patent grant establishes IP rights for SIRPγ inhibitor treatments and may require freedom-to-operate analysis for competing cancer therapy developers.
What to do next
- Monitor for updates
Archived snapshot
Apr 15, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Inhibition of SIRP-gamma for cancer treatment
Grant US12599650B2 Kind: B2 Apr 14, 2026
Assignee
AMGEN INC.
Inventors
Ruozhen Hu, Paolo Manzanillo, Wenjun Ouyang
Abstract
Provided herein are methods of treating a subject with a tumor or cancer. In exemplary embodiments, the method comprises increasing an immune response against the tumor or cancer in the subject or increasing effector activity or reducing suppressive activity of T-cells in the subject. In exemplary embodiments, the method comprises administering to the subject a SIRPγ binder, e.g., SIRPγ inhibitor, in an amount effective to treat the tumor or cancer in the subject.
CPC Classifications
A61K 38/1774 A61K 47/02 A61K 38/177 A61P 35/00 C07K 2317/76 C07K 16/2803
Filing Date
2020-06-23
Application No.
17618922
Claims
9
Related changes
Get daily alerts for USPTO Patent Grants - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Peptides (C07K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.